[Mindray Announces Receipt of Revised Non-binding Proposal to Acquire the Company at US$27 per ADS or US$27 per Ordinary Share The special committee of the Board (the “Special Committee”), formed to consider the original proposal by the Buyer Group, is evaluating this revised proposal with the assistance of its financial and legal advisors. The Special Committee cautions the Company’s shareholders] []

[Mindray Announces Second Quarter 2015 Financial Results Shenzhen, China – August 10, 2015 – Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2015. Highlights for Second Quarter 2015 - Net revenues reached $336.8 million, up from $334.5 million] []

[Mindray Medical Completes Acquisition of Wuhan Dragonbio . 1 About Mindray http://ir.mindray.com We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide] []

[Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio . SHENZHEN, China, July 7, 2015 -- Mindray Medical International Limited (“Mindray”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today a definitive agreement to acquire the remaining stake in Wuhan Dragonbio Surgical Implant Co., Ltd. ("Dragonbio") for approximately US$72.6 million Dragonbio is a domestic] []

[Mindray Announces Formation of a Special Committee to Evaluate “Going Private” Proposal SHENZHEN, China, June 24, 2015 -- Mindray Medical International Limited (“Mindray” or the “Company”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today that its board of directors has formed a special committee (the “Special Committee”) comprised of three independent directors of the] []